Insights
Search Results
Client Highlights
9.24.26
Wilson Sonsini Advises BlackLine on Acquisition of NetNow
On September 21, 2026, BlackLine, the future-ready platform for the office of the chief financial officer that drives digital finance transformation by empowering organizations with accurate, efficient, and intelligent financial operations, announced it has acquired NetNow, an AI-enabled B2B customer onboarding and credit risk management solution. The acquisition expands BlackLine's invoice-to-cash capabilities, bringing automated credit intelligence, AI-enabled risk and fraud detection, and ongoing portfolio monitoring, further upstream in the customer financial lifecycle. Wilson Sonsini Goodrich & Rosati advised BlackLine on the transaction.
Client Highlights
9.10.26
Wilson Sonsini Advises Blaxel on its Acquisition by Baseten
On September 10, 2026, Baseten, an artificial intelligence inference company, announced that it has acquired Blaxel, an infrastructure company building secure, persistent execution environments for AI agents. The acquisition expands Baseten's platform to bring reliable, secure, and cost-effective infrastructure agents need to run code, use tools, and maintain state. Wilson Sonsini Goodrich & Rosati advised Blaxel on the transaction.
Client Highlights
8.26.26
Wilson Sonsini Advises Altruist on Acquisition by Vanguard
On August 26, 2026, Vanguard and Altruist, an AI-forward wealth technology and custody platform serving financial advisors, announced that they have entered into a definitive agreement under which Vanguard will acquire Altruist. Wilson Sonsini Goodrich & Rosati is advising Altruist on the transaction.
Client Highlights
8.25.26
Wilson Sonsini Advises Checkr on Acquisition of Truv
On August 18, 2026, Checkr, an AI-powered verification platform for high-stakes decisions, announced the acquisition of Truv, a consumer-permissioned income, employment, and asset verification company. Wilson Sonsini Goodrich & Rosati advised Checkr on the transaction.
Client Highlights
8.06.26
Wilson Sonsini Advises AiDASH on $350 Million Acquisition by Schneider Electric
On July 30, 2026, Schneider Electric, a global energy technology company, announced it has entered a definitive agreement to acquire AiDASH, a cloud-native software company that provides AI-driven vegetation, asset, and climate risk intelligence to utilities and other critical infrastructure operators, in an all-cash transaction with implied enterprise value of $350 million. Wilson Sonsini Goodrich & Rosati is advising AiDASH on the transaction.
Client Highlights
8.03.26
Wilson Sonsini Advises Firefly Bio on $1 Billion Acquisition by Johnson & Johnson
On July 29, 2026, Johnson & Johnson announced the completion of its acquisition of Firefly Bio, a biotechnology company advancing its proprietary Firelink™ degrader antibody conjugate platform, for $1 billion in cash. The Firelink™ DAC platform expands Johnson & Johnson’s oncology portfolio and advances the company’s ambition to develop targeted therapies for some of the most prevalent and difficult-to-treat solid tumors, including KRAS-driven cancers. Wilson Sonsini Goodrich & Rosati advised Firefly Bio on the transaction.
Client Highlights
7.27.26
Firm Advises Forte Biosciences on $2.2 Billion Acquisition by argenx
On July 27, 2026, argenx, a global immunology innovation company, and Forte Biosciences, a clinical-stage biopharmaceutical company, announced that they have entered into a definitive agreement under which argenx will acquire Forte Biosciences for $77.00 per share in cash, representing a total equity value of approximately $2.2 billion. FB102, Forte Biosciences’ lead program, expands argenx’s portfolio of differentiated immunology medicines, adding a first-in-class anti-CD122 antibody with clinical proof-of-concept in vitiligo and celiac disease and potential to address multiple autoimmune diseases. Wilson Sonsini Goodrich & Rosati advised Forte Biosciences on the transaction.
Client Highlights
7.09.26
Wilson Sonsini Advises Beam Benefits on Acquisition by Principal Financial Group
On July 7, 2026, Principal Financial Group announced an agreement to acquire Beam Benefits, an employee benefits company serving more than 25,000 small businesses. Principal currently serves 180,000 employers, providing comprehensive retirement, benefits, and business owner solutions. The acquisition is expected to close in the latter half of 2026, subject to the completion of customary closing conditions and regulatory approvals. Wilson Sonsini Goodrich & Rosati advised Beam Benefits on the transaction.
Client Highlights
6.24.26
Wilson Sonsini Advises Saturnus Bio on Strategic Collaboration with Merck KGaA, Darmstadt, Germany
On June 23, 2026, Merck KGaA, Darmstadt, Germany, a leading global science and technology company, announced a strategic collaboration with Versant Ventures to launch Saturnus Bio, a next-generation precision cardiology company that utilizes targeted gene modulation to address rare mono-genetic cardiomyopathies with significant unmet need. Wilson Sonsini Goodrich & Rosati advised Saturnus Bio on the transaction.
The research-stage partnership entails a build-to-buy deal structure, including an upfront payment of $50 million from Merck KGaA, Darmstadt, Germany to fund Saturnus Bio’s research activities, securing a minority equity stake in the company, as well as additional success-based preclinical milestones, supporting the development of novel drug candidates for genetic cardiomyopathy patients. Merck KGaA, Darmstadt, Germany has exclusive rights to acquire Saturnus Bio for a pre-determined option payment, in addition to success-based earnouts.
The Wilson Sonsini team that advised Saturnus Bio on the transaction includes:
The research-stage partnership entails a build-to-buy deal structure, including an upfront payment of $50 million from Merck KGaA, Darmstadt, Germany to fund Saturnus Bio’s research activities, securing a minority equity stake in the company, as well as additional success-based preclinical milestones, supporting the development of novel drug candidates for genetic cardiomyopathy patients. Merck KGaA, Darmstadt, Germany has exclusive rights to acquire Saturnus Bio for a pre-determined option payment, in addition to success-based earnouts.
The Wilson Sonsini team that advised Saturnus Bio on the transaction includes:
Client Highlights
6.11.26
Wilson Sonsini Advises Beren Therapeutics P.B.C. on $300 Million Financing, Including Equity and Debt and Royalty Facilities
On June 10, 2026, Beren Therapeutics P.B.C., a leader in cholesterol trafficking biology and cyclodextrin-based therapeutics, announced it has secured $300 million in combined financing. The financing consists of:
Client Highlights
4.29.26
Firm Advises Match Group on $100 Million Investment in Sniffies
On April 27, 2026, Match Group, a leading provider of digital technologies designed to help people make meaningful connections, announced a $100 million investment in Sniffies, a map-based platform serving non-heterosexual men. The investment represents a significant minority ownership stake and includes the option to acquire the remaining equity in the future. Sniffies will continue to operate independently and remain founder-led, with Match Group supporting the team's vision and growth. Wilson Sonsini Goodrich & Rosati advised Match Group on the transaction.